Dose Ranging Study With the Probiotic Combination (VSL#3) in Diarrhea IBS
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00179582 |
Recruitment Status
:
Terminated
(Lack of enrollment)
First Posted
: September 16, 2005
Last Update Posted
: March 6, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
IBS | Drug: VSL#3 | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 180 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Multi-center, Double-blind, Placebo Controlled, Dose Ranging Study With VSL#3 in Diarrhea Predominant IBS Patients |
Actual Study Start Date : | January 2005 |
Actual Primary Completion Date : | January 2006 |
Actual Study Completion Date : | January 2006 |

- Global improvement in IBS symptoms
- Frequency of bowel movements
- Changes in abdominal pain
- Changes in bloating

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- IBS diarrhea
Exclusion Criteria:
- < 18 years of age
- Pregnancy/breast feeding
- concomitant medications to reduce bowel function

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00179582
United States, Massachusetts | |
BIDMC | |
Boston, Massachusetts, United States, 02215 |
Principal Investigator: | Anthony Lembo, MD | Beth Israel Deaconess Medical Center |
Publications of Results:
Responsible Party: | Anthony Lembo, Associate Professor of Medicine, Beth Israel Deaconess Medical Center |
ClinicalTrials.gov Identifier: | NCT00179582 History of Changes |
Other Study ID Numbers: |
2004P000001 VSL1 |
First Posted: | September 16, 2005 Key Record Dates |
Last Update Posted: | March 6, 2017 |
Last Verified: | March 2017 |
Keywords provided by Anthony Lembo, Beth Israel Deaconess Medical Center:
IBS Functional bowel disorder Diarrhea probiotic |
Additional relevant MeSH terms:
Diarrhea Signs and Symptoms, Digestive Signs and Symptoms |